Introduction: Calls for an alternative to valproic acid (VPA) as drug of choice for
INTRODUCTION
The so-called third-generation antiepileptic drugs (AEDs) have not been able to modify the natural history of the disease, but they have demonstrated superior pharmacokinetic, pharmacodynamic, and adverse-effect profiles, improving the quality of life of patients with epilepsy [1, 2] . This improvement is largely attributable to the reduced cognitive or psychiatric adverse effects, which play a key role in the quality of life of patients with epilepsy [3] . [5] [6] [7] . Zonisamide achieved a 50% reduction in these seizures in 72.4%-82% of patients and freedom from seizures in [50% of patients with different types of idiopathic generalized epilepsy (IGE) [4] . These data suggest that ZNS may be an alternative to valproic acid (VPA), which is considered the treatment of choice for this type of epilepsy in most current practice guidelines.
Few data have been published on the cognitive adverse effects of ZNS. The meta-analysis by Chadwick and Marson [8] reported that the most frequent adverse effects of ZNS treatment were ataxia, dizziness, somnolence, nervousness, and anorexia, indicating a predominance of cognitive adverse effects. However, a recent study found no differences between ZNS-and VPA-treated patients in the subjective perception of cognitive or neuropsychiatric adverse effects [9] .
In light of this, the present study was designed to examine possible differences in cognitive adverse effects between ZNS and VPA as monotherapy in patients with IGE.
METHODS

Objectives
The main objective of this clinical investigation was to compare the impact on cognition of monotherapy with ZNS versus VPA in patients with IGE.
Study Design
We conducted a comparative, descriptive, observational, retrospective cohort study in two groups of patients diagnosed with IGE and treated with ZNS (ZNS group) or VPA (VPA group) as monotherapy.
Patient Selection
The antiepileptic treatment during the previous 6 months with VPA C1000 mg/day or ZNS C200 mg/day as monotherapy, capacity to provide clinical data required for the study (according to the judgment of the researcher), and written informed consent to participate in the study. Exclusion criteria were the presence of developmental delay, simultaneous treatment with psychotropic drugs, or other factors that could interfere with the neuropsychological assessment (e.g., praxis-induced seizures during the study or the presence of psychiatric comorbidity that could affect the cognitive evaluation).
Sample Size Calculation
No previous data were available for sample size estimation. Given that the objective was to compare cognitive adverse effects between two treatments, and the imposition of strict inclusion criteria, we aimed to enroll at least eight patients in each group for a preliminary comparison.
Selection of Variables
The following neuropsychological test battery was used for cognitive evaluation in all participants.
Laterality Test
Edinburgh Handedness Inventory [10] Subjects evaluate the use of one or the other hand in different basic activities of daily living using a Likert-type scale (1 = right very preferential; 2 = right preferential; 3 = either hand equally; 4 = left preferential; 5 = left very preferential). Spatial Localization (WMS) [14] The WMS evaluates visual span, visual working memory, and concentration using a board with blocks that are tapped by the examiner in a certain order that the subject must immediately repeat (forward Corsi block test). In a second test, the subject must invert the order in which the blocks are tapped by the examiner (backward Corsi block test).
Test of Attention and Processing Speed
Trail-Making Test A and B [11] These are tests of visual search speed, sustained and divided attention, and cognitive flexibility. Subjects are given a sheet with a series of disordered numbers that they must join together as quickly as possible without lifting the pen from the paper (TMT-A). Subjects are then given another sheet with disordered letters and numbers that they must join together in an alternate manner and in order as quickly as possible (TMT-B).
Stroop Test [15] This test measures processing speed, selective attention, and inhibition. In the first of three parts, subjects must read a series of colors (blue, red, and green; Stroop-C test) as quickly as possible. In the second part, they must name the color of an X-shaped stimulus that is presented (Stroop-P test). In the final part, they are presented with the names of colors written in a different color to that of their name; subjects must name the color in which the word is written, inhibiting its meaning (Stroop-PC test).
Verbal Fluency Test and Executive Functions
Verbal Fluency Test (Phonetics and Semantics) [11] This test yields information on semantic memory, executive functions, and the capacity of subjects to change tasks. Subjects are asked to state in 1 min as many words as they can that begin with ''p''. Next, they are asked to say in 1 min the names of all animals they can remember, regardless of the first letter. [16] We also gathered data from all participants using a standardized data collection form, including age (in years), sex, specific epilepsy syndrome diagnosis, and number of seizures during the previous 3 months. Data were included in a global study database.
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DISCUSSION
This study found no significant differences in cognitive performance between patients with IGE treated with VPA or ZNS as monotherapy, indicating that the treatment decision can be individualized according to effectiveness criteria or other types of adverse effect. Although VPA is the AED of choice in most clinical practice guidelines for IGE, it is associated with teratogenic and adverse esthetic effects (obesity, hirsutism, alopecia) that have an especially negative impact in young women [18, 19] . An increased risk of autism has been reported in the children of epileptic mothers exposed to VPA during pregnancy [20] . Calls for an alternative to VPA [21] have intensified following the recent ILAE recommendation that this drug not be administered to girls or women of childbearing age [22] . ZNS may be a good alternative option in this patient population given its wide action spectrum, including different types of generalized seizures, and its favorable profile of esthetic adverse effects [4] . Nevertheless, perhaps due to certain similarities with topiramate (TPM), ZNS has been considered to have a worse cognitive profile than VPA, despite the absence of studies directly comparing these AEDs. This has contributed to limited administration in patients with IGE because of the important impact of adverse cognitive effects on quality of life [23] . A review of the efficacy and safety of ZNS in combined therapy for focal epilepsy demonstrated a good long-term cognitive tolerability profile [24] , whereas a study of patients treated with ZNS, TPM, or levetiracetam for alcohol abuse disorder observed superior cognitive performance in ZNS-treated versus TPM-treated patients, mainly in relation to processing speed [25] .
However, a recent prospective study in 14 patients with different types of epilepsy found that ZNS treatment impaired performance in memory, attention (TMT A and B), and verbal fluency tests in a dose-dependent manner and that these effects were sustained over time [26] . Hence, published research on the cognitive impact of ZNS is scarce and results controversial.
Although VPA has been commercially available for many years and is widely used in epilepsy treatment, few data have been published on its possible adverse cognitive effects. Meador et al. [27] compared the side effects of phenobarbital (PB), phenytoin (PHT), and VPA and only observed a worse cognitive performance in the PB group, with no differences between the PHT and VPA groups.
The same group found that cognitive adverse effects were slightly worse with TPM than with VPA [28] , and TPM is known to be associated with a poor neuropsychological profile [29] . figure, ROCFLT long-term memory of Rey-Osterrieth complex figure, ROCFST short-term memory of Rey-Osterrieth complex figure, ROCFT execution time of the direct copy of Rey-Osterrieth complex figure, RVLT Rey Verbal Learning Test, VPA valproic acid, ZNS zonisamide * Mann-Whitney U test [31] .
In terms of the visuospatial praxis, both groups showed a similar execution capacity in the ROCFT, but the ZNS group completed it more quickly. These results are interpreted as indicating a superior performance by the ZNS group in complex praxis, i.e., in purely cortical domains.
The VPA group achieved better results (vs. the ZNS group) in the Forward Digit test, which evaluates sustained attention and concentration capacity, whereas no between-group differences were found in the Backward Digit test, which is more closely related to working memory, attention control, and executive attention.
These findings may indicate a slightly worse selective attention or concentration in ZNS-treated patients, with no differences between groups in executive attention. However, no significant between-group differences were found in other attention tests (e.g., Trail-Making or Stroop Tests). The only significant difference in baseline clinical and demographic variables (see Table 1 ) was in sex. The higher proportion of females in the ZNS group (87.5% vs. 12.5%) is attributable to the ILAE recommendations that VPA should be avoided in young women. Nevertheless, this cannot be considered a study bias, because sex is not expected to influence cognitive performance in the studied tasks.
The main limitations of this study are the small sample size, caused by our strict inclusion criteria, and the absence of a baseline cognitive assessment, which would be ideal for the goal that we pursue. However, this is not ethically feasible in clinical practice as it would mean a delay in the start of treatment. On the other hand, it is possible that our study excluded patients with severe cognitive side effects that have not reach 6 months of treatment. However, the analysis of the published series shows no significant difference in retention rates between the two molecules [32, 33] .
As this is the first study to directly compare the cognitive profile of the two monotherapies in real-life settings, other studies may be needed to confirm and refine our results. 
